CanSino Biologics

CanSino Biologics

CanSino Biologics (CanSinoBIO) is a bio pharmaceutical company primarily producing vaccines.

Established in Tianjin, China in 2009, CanSino Biologics (CanSinoBIO) has 450 employees. They currently have 15+ vaccines in their pipeline. Some in pre-clinical, some in NDA (new drug application). These include; meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Since March of 2019, CanSino Biologics has been listed on the Hong Kong Exchange (HKEx). The annual bulk production capacity of the facilities as of 2020 can reach approximately 70 million to 80 million doses.

COVID-19 response

CanSino Biologics, announced in March 2020 that it was close to testing its novel coronavirus vaccine in a clinical trial in China. CanSino’s approach involves taking part of coronavirus’ genetic code and entwining it with a virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. CanSino also markets a vaccine for Ebola virus in China.

In April 2020, CanSino Biologics advanced its vaccine candidate candidate, Ad5-nCoV, into Phase II trials (Chinese registration number: ChiCTR2000030906). CanSino Biologics (CanSinoBIO) is collaborating with the National Research Council of Canada (NRC) to advance bioprocessing and clinical development of vaccine candidate against COVID-19, Ad5-nCoV. Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSinoBIO. A genetically engineering replication-defective adenovirus type 5 vector was used to express the SARS-CoV-2 spike protein which is produced in HEK293 cell lines designed and developed at the NRC. As of May 12, 2020, the vaccine is subject to approval by Health Canada for a Clinical Trial Application being filed by CanSinoBIO. As a preparatory step the Government of Canada announced $44 million in funding to support upgrades to NRC facilities in Montreal to ensure readiness for Canadian bioprocessing of potential vaccine candidates.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
CanSino Biologics Venture round, April 2016
11,000,000
April 1, 2016
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

Products

Product
Website
Launch date
Industry
ChiCTR2000030906
9 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dongxu QIU, PhD

Co-Founder/Executive Director/Senior Vice President

Helen Huihua MAO, PhD

Co-Founder/Senior Vice President

Shou Bai CHAO, PhD

Executive Director/Chief Operating Officer

Tao ZHU, PhD

Co-Founder/Executive Director/Chief Scientific Officer

Xuefeng Yu, PhD

Co-Founder/Chairman/Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BS Web Team
July 13, 2020
@bsindia
Coronavirus vaccine latest update: In a major breakthrough, Russia has become the first nation to complete human clinical trials of a Covid-19 vaccine on humans. Catch latest updates on Covid vaccine
Alex Keown
May 22, 2020
BioSpace
A COVID-19 vaccine candidate under development by China's CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 18, 2020
The Rahnuma Daily
Ottawa, May 17 (IANS) The first Canadian clinical trial for a potential COVID-19 vaccine has been officially approved, according to Canadian Prime Minister Justin Trudeau. At his press conference in Ottawa on Saturday, Trudeau said the Canadian Center for Vaccinology at Dalhousie University has been given the green light by Health Canada to begin clinical trials ...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.